Isotope-Labeled Kinase Inhibitors: Precision Analysis in Targeted Therapy

Overview of Kinase Inhibitors

Kinase inhibitors are a major therapeutic class in oncology and other disease areas. The FDA has approved over 100 kinase inhibitors, primarily for cancer, but also for inflammatory conditions like rheumatoid arthritis (e.g., Baricitinib, Upadacitinib), psoriasis (Deucravacitinib), and alopecia (Ritlecitinib), targeting pathways like EGFR (e.g., Osimertinib), JAK (e.g., Ruxolitinib), BTK (e.g., Ibrutinib), and CDK4/6 (e.g., Palbociclib, Abemaciclib). These targeted therapies block specific kinases driving disease, with families like EGFR, JAK, and VEGFR being highly targeted, though many also hit multiple kinases, revolutionizing personalized medicine.

Quantitative measurements of these small molecules and their metabolites in the various biological matrices are necessary for pharmacokinetics (PK) or toxicology, bioanalysis, and drug-drug interaction studies. Stable isotope-labeled internal standard(s), usually ¹³C and deuterium (²H, "d") labeled compounds, are preferred for LC-MS/MS quantitation and for the support of ADME/metabolism workflows.

At Alfa Chemistry, we are the premier provider of stable isotope-labeled compounds, including a full range of high-purity, stable isotope-labeled (SIL) analogs in order to support pharmaceutical researchers as they conduct unprecedented precision DMPK studies.

Why Use Isotope-Labeled Kinase Inhibitors?

• Quantification Accuracy: Eliminate the "matrix effects" and normal variations during sample preparation and provide highly accurate quantification in complex biological fluids such as plasma or urine.
• Metabolic Profiling: Determination of specific metabolic pathways and metabolites of degradation of the drug by tracing the path of the labeled atom.
• Bioavailability Studies: Used to study the absolute bioavailability and clearance rates of the therapeutic drug in clinical trials.

Featured Isotope-Labeled Products for Precision Research

Alfa Chemistry offers an extensive catalog of labeled kinase inhibitors, covering various targets including EGFR, VEGFR, BCR-ABL, and more. Our products are synthesized with high isotopic enrichment and chemical purity.

Below is a selection of our high-demand stable isotope-labeled inhibitors:

Table 1: Selected Isotope-Labeled Kinase Inhibitors by Therapeutic Area

Innovative Molecules: We also provide specialty labeled compounds such as WNK-IN-11-d3, Dovitinib-d8, Mefatinib-d6, and FHND5071 to support niche research areas in kinase signaling pathways.

Get A Quick Quote

Common Applications for Isotope-Labeled Kinase Inhibitors

• LC-MS/MS quantitative bioanalysis (plasma, urine, tissue): Use matched labeled IS to build robust calibration curves and lower LLOQs.
• PK/TK studies in preclinical and clinical programs: Measure systemic exposure, clearance, volume of distribution.
• ADME / metabolite identification: Track parent-to-metabolite conversion using labeled atoms to pinpoint metabolic soft spots.
• Stable-isotope dilution assays for formulations and stability studies.
• Method validation and QC: Spike labeled IS into QC samples for accuracy/precision monitoring.

Online Inquiry



mg g kg ml L

Isotope-Labeled Kinase Inhibitors: Precision Analysis in Targeted Therapy

SUBMIT